Pharmacology of Insulin Detemir

Endocrinology and Metabolism Clinics of North America

Volumn 36, Issue SUPPL. 1, 2007, Pages 14-20

  Kurtzhals, Peter ^a  

^a Bagsvaerd   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMINO ACID; FATTY ACID; INSULIN; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; LYSINE; MYRISTIC ACID; THREONINE;

ACYLATION; ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BINDING; DRUG DOSAGE FORM COMPARISON; DRUG MECHANISM; DRUG PROTEIN BINDING; GLYCEMIC CONTROL; HUMAN; PRIORITY JOURNAL; RECEPTOR BINDING;

AMINO ACID SEQUENCE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MOLECULAR SEQUENCE DATA;

EID: 34548570767     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8529(07)80004-1     Document Type: Article

References (32)

1. Nathan D., Cleary P., Backlund J.-Y., et al. Intensive diabetes treatment and cardiovasctflax disease in patients with type 1 diabetes. N Engl J Med 353 (2005) 2643-2653
2. Tile Diabetes Control and Complications Trial Research Group. Tile effect of intensive treatment of diabetes oil the development and progression of long-term complications in insulin-dependent diabetes mellims. N Engl J Med 329 (1993) 977-986
3. The DCCT Research Group. Retinopathy and nephropathy in patients with type I diabetes four years after a trial ol intensive therapy. The Diabetes Control and Complications Trial/Epidenliology of Diabetes Interventions and Complications Research Group. N Engl J Med 342 (2000) 381-389
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
5. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metfonmn on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
6. Jehle P., Micheler C., Jehle D., et al. Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens. Lancet 354 (1999) 1604-1607
7. Owens D., Coates P., Luzio S., et al. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 23 (2000) 813-819
8. Heller S., Olsen K., and Draeger E. Within-person variation in fasting blood glucose is correlated to inddence of hypoglycemia in people with type I diabetes treated with insulin detemir and NPH. 64th Annual Scientific Sessions of the American Diabetes Association (June 4-8, 2004) Orlando, Florida. Abstract. A2037-PO
9. Muggeo M., Zoppini G., Bonora E., et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care 23 (2000) 45-50
10. Bolli G., and Owens D. Insulin glargine [commentary]. Lancet 356 (2000) 443-445
11. Heise T., Nosek L., Renn B., et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 53 (2004) 1614-1620
12. Emdin S., Dodson G., Cuffield J., and Cuffield S. Role of zinc in insulin Nosynthesis. Some possible zinc-insulin interactions in the pancreatic B-cell. Diabetologia 19 (1980) 174-182
13. Havelund S., Plum A., Ribel U., et al. The mechanism of protraction of insulin detector, a long-acting, acylated analog of human insulin. Pharm Res 21 (2004) 1498-1504
14. Markussen J., Havelund S., Kurtzhals R., et al. Soluble, fatty acid acylated insulins bind to albmin and show protracted action in pigs. Diabetologia 39 (1996) 281-288
15. Dea M., Hamilton-Wessler M., Ader M., et al. Albumin binding of acylated insulin (NN304) does not deter action to stimulate glucose uptake. Diabetes 51 (2002) 762-769
16. Kurtzhals R. Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir. Int J Obes 28 Suppl 2 (2004) S23-S28
17. Kurtzhals P., Havelund S., Jonassen I., and Markussen I. Effect of fatty acids and sdected drugs on the albumin binding of a long-acting, acylated insulin analogue. J Pharm Sci 86 (1997) 1365-1368
18. Hordern S., Wright J., Umpleby A., et al. Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPtt insulin with a 16-h euglycaemic clamp. Diabetologia 48 (2005) 420.6
19. Slieker L., Brooke G., DiMarchi R., et al. Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia 40 Suppl (1997) S54-S61
20. Kurtzhals R., Schaffer I., Sorensen A., et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49 (2000) 999-1005
21. Plank J., Bodenlenz M., Sinner E., et al. A double-blind, randomized, dose-response study investigating the pharmacodymic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 28 (2005) 1107-1112
22. Brunner G., Sendlhofer G., Wutte A., et al. Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans. Exp Clin Endocrmol Diabetes 108 (2000) 100-105
23. Heinemann L., Sinha K., Weyer C., et al. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med 16 (1999) 332-338
24. Levemir® (insulin detemir [rDNA origin] injection) [prescribing information] (2005), Novo Nordisk A/S, Bagsvaerd, Denmark
25. Hompesch M., Troupin B., Heise T., et al. Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups. Diabetes Obes Metab 8 (2006) 568-573
26. Jhee S., Lyness W., Rojas P., et al. Similarity of insulin detemir pharmacokinetics, safety, and tolerability profiles in healthy Caucasian and Japanese American subjects. J Clin Pharmacol 44 (2004) 258-264
27. Danne T., Lupke K., Walte K., et al. Insulin detemir is characterized by a consistent pharmacoNnetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care 26 (2003) 3087-3092
28. Jacobsen L., Popescu G., and Plum A. Pharmacokinetics of insulin detemir in subjects with renal or hepatic impainnent. Diabetes 51 Suppl 2 (2002) A102 Abstract
29. Bolt S., Tusek C., Jacobsen L., et al. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice dNly administration in subjects with type 1 diabetes. Diabet Med 23 (2006) 522-528
30. Klein O., Lynge J., Endahl L., et al. Insulin detemir and insulin glargine: similar time-action profiles in subjects with type 2 diabetes. Diabetes 55 Suppl 1 (2006) A76 Abstract
31. Klein O., Lynge J., Endahl L., et al. Albumin-bound basal insulin analogues (insulin deteiNr and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 9 (2007) 290-299
32. Philis-Tsimikas A., Charpentier G., Clauson R., et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly comrolled type 2 diabetes. Clin Ther 28 (2006) 1569-1581